Gillette Children's Specialty Healthcare   Report issue

Academic/Hospital Phase 2 Phase 4
Founded: Saint Paul MN United States (1897)

Organization Overview

First Clinical Trial
2012
NCT01607073
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Beverly S. Wical, M.D. | Gillette Children's Specialty Healthcare | Scott Schwantes, M.D.

Active Ingredients

Drugs in Phase 4 Trials (1)

gentamicin (garamycin) (1 trial)

Drugs in Phase 2 Trials (3)

gabapentin (neurontin) (1 trial)

nnz2566 (2 trials)

verapamil (calan) (1 trial)

Drugs in Other Trials (3)

cannabidiol (Epidiolex) (1 trial)

hydroxymethylbutyrate (1 trial)

vitamin d3 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Chronic Pain (Phase 2)

Epilepsies, Myoclonic (Phase 2)

Infections (Phase 4)

Rett Syndrome (Phase 2)

Signs and Symptoms (Phase 2)

Signs and Symptoms, Digestive (Phase 2)

Sleep Initiation and Maintenance Disorders (Phase 2)

Spasms, Infantile (Phase 2)

Syndrome (Phase 2)

Urinary Tract Infections (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 7